Novel pharmacology of substance K-binding sites: a third type of tachykinin receptor.

The tachykinins are a family of peptides with the carboxyl terminal amino acid sequence Phe-X-Gly-Leu-Met-NH2. Three major mammalian tachykinins have been identified--substance K, neuromedin K, and substance P--but only two tachykinin receptors have been postulated. Three tachykinins were labeled with radioiodinated Bolton-Hunter reagent and their binding characteristics were determined in crude membrane suspensions from several tissues. In cerebral cortex labeled eledoisin exhibited high-affinity binding that was inhibited by tachykinins in a manner indicating a definitive SP-E receptor site. In gastrointestinal smooth muscle and bladder, high-affinity binding of labeled substance P was inhibited in a pattern indicating a definitive SP-P site. In intestinal smooth muscle and bladder, however, labeled substance K and labeled eledoisin were both bound in a pattern indicating a preference for substance K itself. The results suggest the existence of three distinct types of tachykinin receptors: SP-P, SP-E, and SP-K.

Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies: role of altered beta-adrenergically mediated protein phosphorylation.

To examine the role of alterations in myofibrillar function in human dilated cardiomyopathies, we determined isometric tension-calcium relations in permeabilized myocytesized myofibrillar preparations (n = 16) obtained from left ventricular biopsies from nine patients with dilated cardiomyopathy (DCM) during cardiac transplantation or left ventricular assist device implantation. Similar preparations (n = 10) were obtained from six normal hearts used for cardiac transplantation. Passive and maximal Ca2+-activated tensions were similar for the two groups. However, the calcium sensitivity of isometric tension was increased in DCM compared to nonfailing preparations ([Ca2+]50=2.46+/-0.49 microM vs 3.24+/-0.51 microM, P < 0.001). In vitro treatment with the catalytic subunit of protein kinase A (PKA) decreased calcium sensitivity of tension to a greater degree in failing than in normal preparations. Further, isometric tension-calcium relations in failing and normal myofibrillar preparations were similar after PKA treatment. These findings suggest that the increased calcium sensitivity of isometric tension in DCM may be due at least in part to a reduction of the beta-adrenergically mediated (PKA-dependent) phosphorylation of myofibrillar regulatory proteins such as troponin I and/or C-protein.

Lipid and membrane interactions of neuropeptide Y.

The interactions of neuropeptide Y with dimyristoylphosphatidylcholine and cell membranes were examined by several physical techniques to probe the potential role of its putative C-terminal amphipathic alpha-helix. Neuropeptide Y binding was demonstrated by a rapid release of entrapped 6-carboxyfluorescein and a rapid decrease in the turbidity of dimyristoylphosphatidylcholine liposomes. In addition, an increase in tyrosine fluorescence intensity and an increase in the anisotropy of diphenylhexatriene in dimyristoylphosphatidylcholine liposomes was observed. In isolated, aortic smooth muscle cell membranes, the anisotropy of diphenylhexatriene increased as a function of added neuropeptide Y. The concentration range (low microM) over which neuropeptide Y increases the polarization of diphenylhexatriene in cell membranes is similar to the range in which it inhibits isoproterenol-stimulated cAMP accumulation. This inhibition is not affected by pertussis toxin, nor does neuropeptide Y cause the release of preloaded [3H]adenine from cells into the medium. These data suggest that neuropeptide Y contains an amphipathic alpha-helical region which interacts with lipids in much the same way as the amphipathic alpha-helical regions of the plasma apolipoproteins and that the inhibition of isoproterenol-stimulated cAMP accumulation at low microM concentrations of peptide may be the result of an alteration in the cell membrane bilayer structure.

A survey of substance P, somatostatin, and neurotensin levels in aging in the rat and human central nervous system.

Levels of the neuropeptides substance P, somatostatin, and neurotensin were measured by radioimmunoassay in regions of the rat and human central nervous system (CNS) in aging. Somatostatin levels were significantly lower only in the corpus striatum of older rats. Substance P levels and neurotensin levels were generally stable with aging as were levels of somatostatin in regions other than the corpus striatum. In post-mortem human CNS tissues, no significant negative correlations of levels of the three peptides were observed with time to refrigeration or time to freezer for the samples. In the human CNS, there were no significant age-related alterations in substance P levels in frontal cortex, thalamus, hypothalamus, caudate nucleus, globus pallidus, or substantia nigra. There was a significant age-related decrease in substance P levels in the human putamen. This age-related decrease was not present in tissues from victims of Huntington's disease nor was there any striking difference in substance P levels as a function of duration of the disease. There were no significant age-related changes in somatostatin levels in human frontal cortex, caudate nucleus, putamen, medial globus pallidus, or substantia nigra. Among these same regions, there was a significant age-related decrease in neurotensin levels only in the pars compacta and pars reticulata of the human nigra. These, results implicate neuropeptides in aging processes in certain regions of the CNS. There are differences between rats and humans with respect to neuropeptides in the aging process in the CNS. Deterioration of some neuropeptide pathways in and to human basal ganglia may be involved in the suspected functional deterioration of parts of the extrapyramidal system in aging.

Design and synthesis of metabolically stable atrial natriuretic factor analogs. Amino- and carboxy-terminal stabilization.

Two analogs of rat atrial natriuretic factor, rANF7-28-NH2 and [Mpr7,Ala20,D-Arg27]rANF7-27-NH2, were prepared by the solid-phase method. These peptides had 2-fold and 7-fold less affinity, respectively, than rANF1-28 in binding to membranes prepared from cultured aortic smooth muscle cells, and both peptides were 5-fold less potent than rANF1-28 in relaxing serotonin-contracted rabbit aortic rings. rANF7-28-NH2 was rapidly degraded by rat kidney homogenates but [Mpr7,Ala20,D-Arg27]rANF7-27-NH2 had enhanced stability against rat kidney homogenate degradation. However, this in vitro stability did not translate into an extended duration of action in vivo.

A new class of high affinity ligands for the neurokinin A NK2 receptor: psi (CH2NR) reduced peptide bond analogues of neurokinin A4-10.

Analogues of [Leu10]NKA4-10 were synthesized in which each of the amide bonds was sequentially replaced with the reduced amide psi (CH2NH) bond to determine the effect of this structural modification on the antagonism of NKA binding to the HUB NK2 receptor. [psi (CH2-NH)9,Leu10]NKA4-10 (6) retained significant affinity for the NK2 receptor (IC50 = 115 nM) and showed weak partial stimulation of PI turnover (approximately 10-15% of NKA maximum). 6 behaves as a competitive antagonist of NKA-stimulated PI turnover with a pA2 = 6.7. The secondary amine of the psi (CH2NH) moiety of 6 was converted to a tertiary amine by alkylation. This modification was found to have a small effect upon receptor affinity but did result in attenuation of partial agonist activity. A combination of amino acid substitutions and psi (CH2NH) alkylation yielded [beta Ala8,psi (CH2N(CH2)2CH3)9,Phe10]NKA4-10 (21) which has very high affinity for the HUB NK2 receptor. This compound inhibited [125I]NKA binding with an IC50 = 1 nM which is equal to the receptor affinity of NKA. Compound 21 also shows very weak partial agonism of PI turnover (< or = 5% of NKA maximum) which makes this the most potent member of a new class of NKA ligands: psi(CH2NR)9-NKA4-10 analogues which potently antagonize NKA binding and possess minimal partial agonist activity.

The rat submaxillary gland contains predominantly P-type tachykinin binding sites.

The specific binding of the 125I-Bolton-Hunter labeled tachykinins substance K (BHSK), eledoisin (BHE), and substance P (BHSP) was examined in crude membrane suspensions and by autoradiography in rat submaxillary gland. All three ligands at 0.1 nM concentrations exhibited binding that was inhibited by tachykinins in a potency rank order of substance P greater than physalaemin greater than substance K greater than eledoisin greater than kassinin greater than neuromedin K with slope factors essentially equal to unity. All tachykinins were 5 to 10 times more potent in inhibiting BHSK and BHE binding compared to BHSP binding. Autoradiographic visualization of BHSK and BHSP binding sites in the gland revealed extensive labeling of mucous and serous acini. The intensity of labeling was much less for BHSK than for BHSP. The results indicate that the rat submaxillary gland contains predominantly P-type tachykinin binding sites.

Binding sites for tachykinin peptides in the brain and stomach of the dogfish, Scyliorhinus canicula.

In membranes of dogfish brain and stomach, two binding sites for tachykinins were identified. One site specifically bound [125I]-Bolton-Hunter substance P (BH-SP) and the rank potency of tachykinins to compete for BH-SP binding revealed similarities with the rank potency of an NK1 receptor. The pharmacology of the other site, which specifically bound [125I]-Bolton-Hunter scyliorhinin II (BH-Scy II), did not resemble any of the mammalian tachykinin receptors. The rank potency to inhibit BH-Scy II binding to this second site was: scyliorhinin II approximately scyliorhinin I greater than eledoisin approximately substance P approximately neurokinin A greater than phyllomedusin approximately physalaemin greater than [Sar9Met(O2)11]substance P. Neurokinin B and senktide did not displace BH-Scy II binding. In addition, nucleotide analogues inhibited BH-SP binding but not BH-Scy II binding. Our binding data suggest the existence of a mammalian-like NK1 receptor and of a nonmammalian tachykinin receptor in the dogfish.

Pharmacologic characterization and autoradiographic distribution of binding sites for iodinated tachykinins in the rat central nervous system.

P-type, E-type, and K-type tachykinin binding sites have been identified in the mammalian CNS. These sites may be tachykinin receptors for which the mammalian neuropeptides substance P, neuromedin K, and substance K are the preferred natural agonists, respectively. In the present investigation, we have compared the pharmacology and the autoradiographic distribution of CNS binding sites for the iodinated (125I-Bolton-Hunter reagent) tachykinins substance P, eledoisin, neuromedin K, and substance K. Iodinated eledoisin and neuromedin K exhibited an E-type binding pattern in cortical membranes. Iodinated eledoisin, neuromedin K, and substance K each labeled sites that had a similar distribution but one that was considerably different from that of sites labeled by iodinated substance P. CNS regions where there were detectable densities of binding sites for iodinated eledoisin, neuromedin K, and substance K and few or no sites for iodinated substance P included cortical layers IV-VI, mediolateral septum, supraoptic and paraventricular nuclei, interpeduncular nucleus, ventral tegmental area, and substantia nigra pars compacta. Binding sites for SP were generally more widespread in the CNS. CNS regions where there was a substantial density of binding sites for iodinated substance P and few or no sites for iodinated eledoisin, neuromedin K, and substance K included cortical layers I and II, olfactory tubercle, nucleus accumbens, caudate-putamen, globus pallidus, medial and lateral septum, endopiriform nucleus, rostral thalamus, medial and lateral preoptic nuclei, arcuate nucleus, dorsal raphe nucleus, dorsal parabrachial nucleus, parabigeminal nucleus, cerebellum, inferior olive, nucleus ambiguus, retrofacial and reticular nuclei, and spinal cord autonomic and somatic motor nuclei. In the brainstem, iodinated substance P labeled sites in both sensory and motor nuclei whereas iodinated eledoisin, neuromedin K, and substance K labeled primarily sensory nuclei. Our results are consistent with either of two alternatives: (1) that iodinated eledoisin, neuromedin K, and substance K bind to the same receptor site in the rat CNS, or (2) that they bind to multiple types of receptor sites with very similar distribution.

Distinct binding sites for substance P and neurokinin A (substance K): co-transmitters in rat brain.

The distribution of binding sites in rat brain for iodinated neurokinin A and iodinated substance P were compared using autoradiography. Distinct patterns of binding for the two iodinated tachykinins were noted. Binding sites for iodinated neurokinin A were noted in the olfactory bulb, cortex, supraoptic n., paraventricular n., certain amygdaloid n., hippocampus, medial habenula, interpeduncular n., n. of the tractus solitarius, and dorsal horn of the spinal cord. This pattern was in contrast to low levels of binding of iodinated substance P to the cortex, supraoptic n., paraventricular n., and the interpeduncular n., but substantial density of binding sites in numerous other regions.

Differential sensitivity to phenoxybenzamine alkylation among types of neurokinin binding sites.

The effect of phenoxybenzamine (PBZ) treatment of crude membranes was examined on binding to neurokinin/tachykinin NK-1, NK-2, and NK-3 binding sites. PBZ in concentrations up to 300 microM resulted in only a slight reduction in Bmax in binding of iodinated substance P to NK-1 sites in rat submaxillary gland and in rat urinary bladder. PBZ in concentrations as low as 30 microM resulted in a decrease in Bmax or in affinity in binding of iodinated neurokinin A (substance K) to NK-2 sites in hamster bladder and in rat bladder, and a decrease in affinity in binding of iodinated eledoisin to NK-3 sites in rat cerebral cortex. The results indicate a parallelism in differential sensitivity to PBZ alkylation between neurokinin biological receptors and neurokinin ligand binding sites.

The synthesis, physical characterization and receptor binding affinity of neuropeptide Y (NPY).

Porcine neuropeptide Y (pNPY) was synthesized by solid-phase techniques and purified by gel filtration and reverse-phase high performance liquid chromatography. It was found to be equipotent to commercial pNPY (Peninsula) in a receptor binding assay (IC50 = 5 nM). Circular dichroic (CD) spectra of the peptide indicates a concentration-independent alpha-helical conformation in aqueous solution ([theta]222 = -13,998, 2.9 X 10(-5) M in 0.1 M sodium phosphate, pH = 8.0). Lowering the pH of the solution to 6.0 produced little change in the CD spectrum, but CD spectra at pH = 4.2 and 1.8 indicated a loss of alpha-helical content of the peptide with decreasing pH. Sedimentation equilibria of synthetic pNPY showed that it is neither wholly monomeric nor dimeric at pH = 4.2 and 8.0. These data suggest an intramolecularly stabilized helical structure similar to the crystal structure of the homologous avian pancreatic polypeptide (APP).

C-terminal modifications of neuropeptide Y and its analogs leading to selectivity for the mouse brain receptor over the porcine spleen receptor.

Neuropeptide Y (NPY) is known to bind to at least two types of receptors (Y1 & Y2). One type (Y2) is able to bind and undergo activation by both NPY and its C-terminal fragments with good potency while the other (Y1) requires the full length of NPY for good potency. For most NPY analogs that have been examined, potency for the Y2 system (porcine spleen) is greater than or equal to that for the Y1 system (mouse brain), since the Y2 system is generally less selective. However, modifications of NPY and its analogs at position 34 can lead to materials with some Y1 selectivity. For example, [Pro34]-pNPY binds to mouse brain with an affinity of 0.14 nM. Its affinity for porcine spleen is 140 nM. [His34]-pNPY was also found to be Y1 selective (19-fold), but not to the degree of the [Pro34] analog (1000-fold). The Pro34 modification in the Y2 selective C-terminal fragment NPY (20-36) converted it into an essentially non-selective analog. The selectivity from the Pro34 substitution results from a loss of Y2 binding potency along with little effect on the Y1-receptor binding. Therefore, Y1 and Y2 receptors have differing requirements for the C-terminal region of NPY in addition to their different requirements for NPY's N-terminus.

Development of an anti-idiotypic antibody that blocks substance P primary antibodies and substance P membrane binding.

Polyclonal antibodies against substance P were raised in rabbits and partially purified. This apparently homogeneous immunoglobulin fraction was used to immunize other rabbits. The anti-idiotypic antibodies derived from these rabbits were substantially more effective in competing with substance P than in competing with beta-endorphin for binding to their respective primary antibodies. The anti-idiotypic antibody was also 50 times more potent in competing with substance P binding than in competing with substance K binding to rat duodenal membranes, a tissue containing receptors for substance P and substance K. The anti-idiotypic antibodies exhibited significant enhancement of substance P induced spasmogenic response on the rat uterus and guinea pig ileum (GPI). The results indicate that it is possible to develop anti-idiotypic antibodies that recognize substance P receptors. These antibodies will be of value in studies of the physiological roles of the neuropeptide, substance P.

Depletion of primary afferent substance P by capsaicin and dihydrocapsaicin without altered thermal sensitivity in rats.

Systemic administration of capsaicin and dihydrocapsaicin to adult rats of two different strains and of capsaicin to neonatal rats, depleted substance P levels in dorsal roots plus ganglia and in dorsal spinal cord. In no case was this depletion accompanied by substantially altered tail-flick latencies. The results are not consistent with a role of the neuropeptide in nociceptive thermal sensitivity in the rat.

The normal occurrence of octopamine in the central nervous system of the rat.

An enzymatic assay for octopamine capable of detecting 50 pg of amine was developed and used to study the distribution of octopamine in regions of the rat central nervous system. The presence of octopamine in the rat pineal organ was confirmed by mass spectrometry; Administration of a monoamine oxidase inhibitor and of tyramine led to increases in CNS octopamine levels while the administration of reserpine intraperitoneally or 6-hydroxydopamine intraventricularly led to decreases in octopamine levels. The results suggest that in the mammalian CNS octopamine is present in neural structures where it may be involved in synaptic function.

Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.

Substance P (SP) levels were determined by radioimmunoassay (RIA) in several regions of post-mortem brain of controls and Huntington's disease (HD) patients. In controls, highest SP levels were found in basal ganglia, substantia nigra and hypothalamus. Nigral pars reticulata contained 3--4-fold higher levels than pars compacta. In HD, SP levels were reduced in all basal ganglia and substantia nigra. The reductions ranged from 48% in caudate nucleus to over 90% in nigral pars reticulata. There were no changes in SP levels in HD frontal cortex, thalamus or hypothalamus.

Capsaicinoid-induced local and systemic antinociception without substance P depletion.

Capsaicin and its analog, dihydrocapsaicin, produced chemogenic and thermal antinociception and depletion of substance P from the dorsal spinal cord and dorsal root ganglia of guinea pigs following a single parenteral dose. Time course and distribution studies indicated that capsaicinoid-induced antinociception resulted from neither depletion of substance P nor nonspecific actions of capsaicinoids at dorsal root ganglia. A site of action for capsaicinoid-induced antinociception is peripheral to the dorsal root ganglia and may involve covalent binding of capsaicinoids to free nerve endings of the dermis. Depletion of substance P by capsaicinoids appears to be mediated at a site more central than that which mediates antinociception and may involve alterations in the retrograde axoplasmic transport of neurotrophic factors.

Regulation of substance P by nerve growth factor: disruption by capsaicin.

Capsaicin depleted substance P from guinea pig dorsal root ganglia and inhibited the retrograde axoplasmic transport of nerve growth factor (NGF). Doses of capsaicin which depleted substance P also inhibited the retrograde axoplasmic transport of NGF. Inhibition of the retrograde transport of NGF by capsaicin preceded substance P depletion. Supplementation of guinea pigs with mouse NGF completely prevented capsaicin-induced substance P depletion. It is concluded that capsaicin depletes substance P from primary afferent neurons of the adult guinea pig by altering the availability of NGF. The data support a role for NGF in the normal maintenance of neuropeptide levels in some sensory neurons in the adult animal.

The dogfish peptides scyliorhinin I and scyliorhinin II bind with differential selectivity to mammalian tachykinin receptors.

The dogfish intestinal, linear tachykinin scyliorhinin I (SCYI) and cyclic tachykinin scyliorhinin II (SCYII) bound with differential selectivity to mammalian tachykinin, membrane receptor sites. SCYI bound with highest affinity to NK-1 sites in rat submandibular gland (KI = 0.9 nM) and to NK-2 sites in hamster urinary bladder (KI = 2 nM) whereas SCYII bound with highest affinity to NK-3 sites in rat cerebral cortex (KI = 2.5 nM). These results suggest that SCYI is a dual NK-1/NK-2 tachykinin receptor agonist while SCYII is an NK-3 selective tachykinin receptor agonist.